A stable liposomal formulation for ocular delivery of an alpha 2 adrenergic agonist. The formulation contains a liposome that includes a lipid bilayer including a phosphatidylcholine. An alpha 2 adrenergic agonist is encapsulated in the liposome. Also provided is a method for treating an ocular disorder by administering to the eye the stable liposomal formulation